Buy & Sell Funko Inc (FNKO) – Funko Inc Price Today
Aura AI Summary
Key Stats
- $290.92MMarket Cap
- Consumer StaplesSector
- -41.4%3M Drawdown
- $535.96MEnterprise Value
- -Dividend Yield
- 29 daysTypical Hold Time
Funko Inc (FNKO) is currently valued at a market capitalization of $290.92M, with an enterprise value of $535.96M. Over the past 52 weeks, Funko Inc has traded between a low of $2.46 and a high of $5.54, highlighting its annual price range. Over the past three months, Funko Inc has recorded a drawdown of -41.4%, reflecting recent price volatility. On average, investors hold Funko Inc for approximately 29 days, indicating typical investor behavior on the platform.
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Most Recent News
Bempedoic acid shows promise in lowering LDL-C in children and statin-intolerant adults, per Esperion data.
Esperion Therapeutics presented new data at the 2026 European Atherosclerosis Society Congress showing bempedoic acid effectively lowers LDL cholesterol in children aged 6-17 with familial hypercholesterolemia and is well tolerated. A secondary analy...

Rhythm Pharmaceuticals to present at major healthcare conferences in June 2026
Rhythm Pharmaceuticals announced that its CEO and CFO will participate in fireside chats at the Jefferies Global Healthcare Conference on June 4 and the Goldman Sachs Global Healthcare Conference on June 8, 2026. These events will be webcast and acce...

Virax Biolabs reports positive early data for ViraxImmune™, a test for Long COVID and related syndromes.
Virax Biolabs announced encouraging early pilot data for ViraxImmune™, a blood test in development to detect Long COVID, ME/CFS, and related post-acute infection syndromes. The test showed 88% specificity and 92% positive predictive value in distingu...
